A Study to Assess the Efficacy and Safety of Pegcetacoplan for the Prevention of Recurrent C3G or Primary IC-MPGN in Kidney Transplant Recipients (PRESERVE)
A 2-year, Single-arm, Multi-center Study to Explore the Efficacy and Safety of Pegcetacoplan in Preventing Disease Recurrence in Adolescent and Adult Kidney Transplant Recipients With C3 Glomerulopathy or Primary Immune-complex Membranoproliferative Glomerulonephritis
To assess the efficacy and safety of pegcetacoplan for the prevention of recurrent C3G or primary IC-MPGN in kidney transplant recipients
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
The PRESERVE study is a Phase 3b, multicenter, single-arm, open-label clinical trial designed to explore the efficacy and safety of pegcetacoplan in preventing or delaying the recurrence of C3 glomerulopathy (C3G) or primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN) following kidney transplantation. Recurrence of these diseases after transplantation is common and can lead to graft dysfunction and loss. Pegcetacoplan is a complement C3/C3b inhibitor that has demonstrated activity in patients with native kidney disease and recurrent disease after transplantation. The study aims to assess whether initiating pegcetacoplan at the time of kidney transplantation, before recurrence occurs, may delay the recurrence and support long-term graft outcomes. Participants will receive pegcetacoplan in addition to standard post-transplant care and will be followed to evaluate disease recurrence, kidney function, graft outcomes, safety, and tolerability.
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Contact
Study Contact
- Name: Study Physician
- Phone Number: +46 86972000
- Email: medical.info@sobi.com
Study Locations
-
-
Pernambuco
-
Recife, Pernambuco, Brazil, 52010-010
- Not yet recruiting
- Real Hospital Português
-
-
São Paulo
-
Botucatu, São Paulo, Brazil, 18618-970
- Not yet recruiting
- UNESP - Faculdade de Medicina da Universidade Estadual Paulista - Campus Botucatu
-
São Paulo, São Paulo, Brazil, 05403-000
- Not yet recruiting
- Hospital das Clinicas da Faculdade de Medicina da USP - HCFMUSP
-
-
-
-
Alberta
-
Edmonton, Alberta, Canada, T6G 2R7
- Not yet recruiting
- University of Alberta - Faculty of Medicine & Dentistry
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V6Z 1Y6
- Not yet recruiting
- St. Paul's Hospital
-
-
Ontario
-
London, Ontario, Canada, N6A 5A5
- Not yet recruiting
- London Health Sciences Centre (LHSC) - University Hospital
-
Toronto, Ontario, Canada, M5G 2C4
- Not yet recruiting
- Toronto General Hospital
-
-
Quebec
-
Montreal, Quebec, Canada, H4A 3J1
- Not yet recruiting
- McGill University Health Centre Research Institute
-
-
-
-
-
Helsinki, Finland, 290
- Not yet recruiting
- Helsinki University Central Hospital
-
-
-
-
Bas Rhin
-
Strasbourg, Bas Rhin, France, 67091
- Not yet recruiting
- CHU Strasbourg - Nouvel Hôpital Civil
-
-
Haute Garonne
-
Toulouse, Haute Garonne, France, 31059
- Not yet recruiting
- Hopital Rangueil
-
-
Herault
-
Montpellier, Herault, France, 34000
- Not yet recruiting
- Hopital Lapeyronie pt
-
-
Nord
-
Lille, Nord, France, 59037
- Not yet recruiting
- Hopital Claude Huriez - CHU Lille
-
-
Paris
-
Paris, Paris, France, 75015
- Not yet recruiting
- Hôpital Necker - Enfants Malades
-
-
Rhone
-
Lyon, Rhone, France, 69437
- Not yet recruiting
- Hopital Edouard Herriot - CHU Lyon
-
-
-
-
Lower Saxony
-
Hanover, Lower Saxony, Germany, 30625
- Not yet recruiting
- Medizinische Hochschule Hannover
-
-
North Rhine-Westphalia
-
Cologne, North Rhine-Westphalia, Germany, 50937
- Not yet recruiting
- Universitaetsklinikum Koeln
-
Essen, North Rhine-Westphalia, Germany, 45147
- Not yet recruiting
- Universitaetsklinikum Essen
-
-
-
-
Bari
-
Bari, Bari, Italy, 70124
- Not yet recruiting
- Azienda Ospedaliero Universitaria Consorziale Policlinico di Bari
-
-
Bergamo
-
Bergamo, Bergamo, Italy, 24127
- Not yet recruiting
- Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII (Presidio Papa Giovanni XXIII)
-
-
Roma
-
Roma, Roma, Italy, 165
- Not yet recruiting
- Ospedale Pediatrico Bambino Gesù
-
Roma, Roma, Italy, 168
- Not yet recruiting
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
-
-
-
-
-
Riyadh, Saudi Arabia, 11211
- Not yet recruiting
- King Faisal Specialist Hospital & Research Center
-
-
-
-
Barcelona
-
Barcelona, Barcelona, Spain, 8035
- Not yet recruiting
- Hospital Universitari Vall d'Hebron - VHIR
-
-
La Coruña
-
A Coruña, La Coruña, Spain, 15006
- Not yet recruiting
- Complejo Hospitalario Universitario A Coruña
-
-
Madrid
-
Madrid, Madrid, Spain, 28041
- Not yet recruiting
- Hospital Universitario 12 de Octubre
-
-
Málaga
-
Málaga, Málaga, Spain, 29010
- Not yet recruiting
- Hospital Regional Universitario de Malaga
-
-
Vizcaya
-
Barakaldo, Vizcaya, Spain, 48903
- Not yet recruiting
- Hospital de Cruces
-
-
-
-
-
Lausanne, Switzerland, 1011
- Not yet recruiting
- Centre Hospitalier Universitaire Vaudois (CHUV)
-
-
-
-
Greater London
-
London, Greater London, United Kingdom, W12 0HS
- Recruiting
- Hammersmith Hospital
-
London, Greater London, United Kingdom, NW3 2QG
- Not yet recruiting
- Royal Free Hospital
-
-
Greater Manchester
-
Manchester, Greater Manchester, United Kingdom, M13 9WL
- Not yet recruiting
- Manchester Royal Infirmary
-
-
Tyne & Wear
-
Newcastle upon Tyne, Tyne & Wear, United Kingdom, NE7 7DN
- Not yet recruiting
- Freeman Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female patients with a diagnosis of C3 glomerulopathy (C3G) or primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN) who are planning to undergo kidney transplantation because of the disease.
- Have a high risk of disease recurrence following kidney transplantation, based on either having a previous kidney allograft loss due to recurrence of C3G or primary IC-MPGN, or assessed as having a high risk by the investigator based on other clinical information.
- Is fully vaccinated and up to date with their vaccinations against Neisseria meningitidis, Streptococcus pneumoniae, and Haemophilus influenzae type B, in accordance with local guidelines, at the time of initiating pegcetacoplan.
Exclusion Criteria:
- A known secondary cause for MPGN, including but not limited to monoclonal gammopathy of clinical significance, hepatitis B, hepatitis C, or autoimmune cryoglobulinemia.
- History of invasive meningococcal disease.
- History of malignancy, except for the following: cured basal or squamous cell skin cancer, curatively treated in situ disease, or currently malignancy-free and has been off-treatment for the malignancy for at least 5 years.
- Hypersensitivity to pegcetacoplan or any of its excipients.
- Known or suspected hereditary fructose intolerance.
- Any other medical condition which, in the opinion of the Investigator, makes the participant unsuitable for inclusion.
- Use of a complement inhibitor for the treatment of C3G or primary IC-MPGN within 1 month prior to the scheduled kidney transplantation surgery.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Pegcetacoplan
Pegcetacoplan, a complement C3/C3b inhibitor, administered according to the study protocol in kidney transplant recipients with high risk of recurring C3G or primary IC-MPGN |
Dose amount based on age and weight Subcutaneous infusion twice-a-week. Adult participants aged 18 years or older at enrolment: 1080 mg Adolescent participants aged 12 to 17 years at enrolment:
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Occurrence of Clinically Significant Recurrent Disease
Time Frame: Within 2 years after kidney transplantation
|
Histological evidence of recurrent disease based on the histopathological assessment of the kidney biopsy |
Within 2 years after kidney transplantation
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Time to Onset of Clinically Significant Disease Recurrence
Time Frame: Up to 2 years after kidney transplantation
|
To explore the impact of pegcetacoplan on time to clinically significant recurrence of C3G or primary IC-MPGN after kidney transplantation |
Up to 2 years after kidney transplantation
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Study Director: Study Physician, Swedish Orphan Biovitrum AB (publ)
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- Sobi.PEGCET-404
- 2026-526392-39-00 (Ctis)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Qualified researchers may request access to patient level data and related study documents.
All requests are evaluated by a cross functional panel of experts within Sobi. Patient level data will be anonymized and study documents, if applicable, will be redacted to protect the privacy of trial participants.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.